Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...

But this came with a drawback: individuals who have the new gene variants (called APOL1 G1 and G2) also have an increased risk of developing kidney disease. Over the last two decades there has ...

In March, two biotechnology companies were given the greenlight by the Food and Drug Administration, or FDA, to conduct ...

A Diabetes, Heart Failure, and Kidney Disease Medication Is the First of ... that having just one risk variant in a gene known as APOL1 can ... Oct. 23, 2024 — According to a study, the RNA ...

In November 2024, Maze closed an oversubscribed $115 million Series D financing co-led by Frazier Life Sciences and Deep Track Capital, with participation from Janus Henderson Investors and Logos ...

Maze Therapeutics, a kidney disease therapy developer, recently IPO-ed with a market cap of $487mn and significant early-stage investor backing. Lead asset MZE829 targets APOL1 Kidney Disease ...

In the kidney disease category, its pipeline includes inaxapalin (VX-147) for APOL1-mediated kidney disease, in phase 3, and early-stage candidate VX-407 for autosomal dominant polycystic kidney ...

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 ...

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 ...